Yu Kanemaru

Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy

Yu Kanemaru, Manabu Natsumeda, Masayasu Okada et al. · Acta Neuropathologica Communications · 2019 · 69 citations · Full text

Medicine, Molecular Genetics, Oncology +16

High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas

Jun Watanabe, Manabu Natsumeda, Masayasu Okada et al. · JCO Precision Oncology · 2019 · 58 citations

Medicine, Molecular Genetics, Oncology +17

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas

Hideaki Abe, Manabu Natsumeda, Masayasu Okada et al. · Frontiers in Oncology · 2020 · 44 citations · Full text

Medicine, Molecular Biology, Oncology +16

Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas

Jotaro On, Manabu Natsumeda, Jun Watanabe et al. · Diagnostics · 2021 · 15 citations · Full text

Medicine, Neurology, Oncology +17

Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features

Manabu Natsumeda, Michael Chang, Ramil Gabdulkhaev et al. · Brain Tumor Pathology · 2021 · 13 citations

Medicine, Molecular Genetics, Oncology +14